- Home
- PRQR vs ETON Comparison
PRQR vs ETON Comparison
Compare PRQR & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- ETON
- Stock Information
- Founded
- PRQR 2012
- ETON 2017
- Country
- PRQR Netherlands
- ETON United States
- Employees
- PRQR N/A
- ETON N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- ETON Health Care
- Exchange
- PRQR Nasdaq
- ETON Nasdaq
- Market Cap
- PRQR 309.5M
- ETON 329.8M
- IPO Year
- PRQR 2014
- ETON 2018
- Fundamental
- Price
- PRQR $1.65
- ETON $14.22
- Analyst Decision
- PRQR Strong Buy
- ETON Strong Buy
- Analyst Count
- PRQR 6
- ETON 3
- Target Price
- PRQR $8.50
- ETON $27.67
- AVG Volume (30 Days)
- PRQR 448.8K
- ETON 248.9K
- Earning Date
- PRQR 03-13-2025
- ETON 03-18-2025
- Dividend Yield
- PRQR N/A
- ETON N/A
- EPS Growth
- PRQR N/A
- ETON N/A
- EPS
- PRQR N/A
- ETON N/A
- Revenue
- PRQR $20,235,014.00
- ETON $39,011,000.00
- Revenue This Year
- PRQR $39.44
- ETON $107.69
- Revenue Next Year
- PRQR N/A
- ETON $65.50
- P/E Ratio
- PRQR N/A
- ETON N/A
- Revenue Growth
- PRQR 196.41
- ETON 23.29
- 52 Week Low
- PRQR $1.59
- ETON $3.03
- 52 Week High
- PRQR $4.62
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- PRQR 28.26
- ETON 43.84
- Support Level
- PRQR $1.78
- ETON $12.73
- Resistance Level
- PRQR $1.87
- ETON $15.73
- Average True Range (ATR)
- PRQR 0.11
- ETON 0.93
- MACD
- PRQR -0.02
- ETON -0.01
- Stochastic Oscillator
- PRQR 10.53
- ETON 49.67
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.